ATENEA-Co-300 study

Phase 1

• Conditions: Confirmed patients to COVID-19; COVID-19; SARS-CoV2; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases

• Registration Number: RPCEC00000317
• Lead Sponsor: Center for Genetic Engineering and Biotechnology (CIGB), in Havana

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-28
• Study Completion: 2020-07-17
• Results First Posted: 2020-07-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1) Patients who meet the diagnostic criteria for COVID 19 in categories 1 through 4 of the NIH guidelines.
2) Age over 18 years.
3) Voluntariness of the patient by signing the informed consent.

Exclusion Criteria

1) Pregnancy or lactation at the time of inclusion in the study.
2) Patients included in another clinical trial.
3) Diseases that compromise the patient's state of consciousness or their possibility of giving their informed consent or collaborating in the trial.
4) Critical illness, category 5 of the NIH Guidelines.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction of the time to the negativization of the coronavirus detection test (time to the negative of the coronavirus detection test by PCR-RT in the nasopharynx). Measurement time: 48 hours and on the 7th day after starting the treatment.